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It is generally accepted that a correlation between neurodegenerative disease and protein aggregation in the brain exists; however, a
causal relationship has not been elucidated. In neurons, failure of autophagy may result in the accumulation of aggregate-prone
proteins and subsequent neurodegeneration. Thus, pharmacological induction of autophagy to enhance the clearance of intra-
cytoplasmic aggregate-prone proteins has been considered as a therapeutic strategy to ameliorate pathology in cell and animal
models of neurodegenerative disorders. However, autophagy has also been found to be a factor in the onset of these diseases, which
raises the question of whether autophagy induction is an eﬀective therapeutic strategy, or, on the contrary, can result in cell death.
In this paper, we will first describe the autophagic machinery, and we will consider the literature to discuss the neuroprotective
eﬀects of autophagy.
1. Introduction
Autophagy was initially reported more than 40 years ago [1].
It is a physiological process by which cells remove damaged
proteins and organelles through lysosomal degradation. This
system prevents the accumulation of products that are not
only useless, but potentially toxic. In neurons, this process
is considered particularly important since neurons do not
replicate; therefore, eventual damaging proteins will not be
diluted in subsequent divisions. Autophagy is distinctly reg-
ulated in neuronal and nonneuronal cells [2, 3], and recent
studies have linked autophagic pathways to several patho-
logical conditions ranging from cancer to neurodegenerative
disorders [3, 4]. Moreover, impairment of basal autophagy
results in neuronal death [5, 6]. Interestingly, accumulation
of proteins is a common feature in several neurodegene-
rative diseases such as Alzheimer’s disease (AD), Parkinson’s
disease (PD), and Huntington’s disease (HD). In AD, hyper-
phosphorylated tau-containing neurofibrillar tangles and
Aβ deposits are found; in PD, aggregated α-synuclein is a
major component in the Lewy bodies; in HD, N-terminal
fragments of mutant huntingtin protein (Htt) are found
in intracellular inclusion bodies. These findings led to
hypothesize that alterations in the autophagic process were
responsible for the aggregation of these toxic proteins and
consequently to the onset of disease. According to this idea,
several reports document an amelioration of toxicity with
removal of accumulation of aggregates (for review see [7]).
However, other reports challenge this view and suggest that
aggregation of toxic products is not correlated with the
degree of neurodegeneration; therefore, protein aggregates
are considered an epiphenomenon of the disease, not an
underlying factor [8–10]. The literature provides enough evi-
dence to feed controversy; in this paper, we will review the
data related to the eﬀects of autophagy on neuroprotection,
in particular in connection with PD.
2. Autophagy Classification
Based on how the proteins reach the lysosome, autophagy
can be classified as (i) macroautophagy, (ii) microautophagy
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Figure 1: Schematic depiction of the three types of autophagy. (a) Chaperone-mediated autophagy. The cytosolic chaperone protein HSC 70
binds to the substrate protein; the consensus sequence LysPheGluArgGln of the substrate-chaperone complex is recognized by LAMP-2A, a
lysosomal membrane receptor. The protein substrate is then unfolded and translocated across the lysosomal membrane to be degraded inside
the lysosome. (b) Macroautophagy. Cytosolic material is sequestered by an expanding membrane sac (phagophore) forming a double-mem-
brane vesicle, an autophagosome. Fusion of the autophagosome to the lysosome will expose the content of the autophagosome to lysosomal
hydrolases. (c) Microautophagy. Small proteins can be engulfed directly by the lysosome without intermediate vesicles.
and (iii) chaperone-mediated autophagy CMA (Figure 1)
[11].
(i) Macroautophagy, usually identified simply as auto-
phagy, is the strategy commonly used for bulk deg-
radation of cytoplasmic proteins and organelles
(including dysfunctional mitochondria, which some-
times are referred as mitophagy). It is generally con-
sidered to be a nonspecific process in organisms from
yeast to humans (with exceptions) and is a multistep
process, where the formation of the double-mem-
brane autophagic vacuoles (AVs) or autophagosomes
occurs first. These vesicles surround the organelles
or proteins to be degraded [12] and later fuse with
endosomes to form an intermediate type of vesicle
(amphisomes), or directly to lysosomes (autopha-
golysosomes), where the content will be finally deg-
raded [4]. Macroautophagy can also be induced
under conditions of physiological stress, like starva-
tion [13]. The proteins regulating the whole process
are autophagy-related proteins (Atg in yeast, ATG in
mammals) which were discovered in yeast and have
been found highly conserved. Up to date, more than
30Atg proteins in mammals are known to participate
in this intricate process (for review [11]).
(ii) Microautophagy is a much simpler process and
occurs when lysosomes engulf cytosolic components
directly by membrane involution [14, 15].
(iii) Finally, chaperone-mediated autophagy (CMA)
incorporates cytosolic proteins that are brought by
chaperones to the lysosome membrane (for review
[16]). All the CMA substrates described so far are
soluble cytosolic proteins containing a consensus
sequence Lys-Phe-Glu-Arg-Gln (KFERQ) [17]. This
motif (present in approximately 30% of cytosolic
proteins) is recognized by a cytosolic chaperone,
heat-shock cognate protein 70 (Hsc70), which trans-
fers protein substrates to the lysosomal membrane,
and there, through binding to the receptor lysosome-
associated membrane protein-2A (LAMP-2A), they
are translocated into the lysosome.
2.1. Autophagy versus Proteasome-Mediated Protein Degra-
dation. Proteasomes are barrel-shaped protein complexes
that mainly degrade small, short-lived nuclear and cytosolic
proteins [18]. The ubiquitin-proteasome system is also
important for the degradation of misfolded proteins in the
endoplasmic reticulum [19]. Most proteins are targeted for
proteasomal degradation after being covalently modified
with ubiquitin. However, substrates need to be unfolded
to pass through the narrow pore of the proteasome barrel,
which hinders the clearance of oligomeric and aggregated
proteins [20]. Under normal circumstances, the ubiquitin-
proteasome system is more eﬃcient than basal levels of
macroautophagy, so for proteins that have access to both
pathways, proteasomes are the favored clearance route. How-
ever, when a cytosolic protein is susceptible of aggregation,
and therefore a poor proteasome substrate, macroautophagy
will become the dominant clearance route [21]. This suggests
that dependence of proteins on themacroautophagy pathway
for their clearance correlates with their propensity to aggre-
gate [22]. On the other hand, impairment of proteasome
pathways has been associated with PD [23, 24] and HD
[25]. Moreover, systemic exposure to proteasome inhibitors
induces a model of Parkinson [23]. Therefore, it is not
surprising that one of the most studied genes associated with
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familial PD was parkin, which encodes for an Ubiquitin-
protein ligase [26]. However, whether proteasomal impair-
ment is a key stepin familial or sporadic PD in which there
are no primary defects in the ubiquitin-proteasome pathway
is still not clear.
3. Proteasome and Protein Aggregates:
Macroautophagy
Maybe as a consequence of proteasome impairment, or other
reasons in familial forms of PD, aggregates of α-synuclein
forming the characteristic Lewy bodies (LB) are found.
Furthermore, mutant forms of α-synuclein are strongly
dependent on the macroautophagy pathway [22, 27]. Con-
firming these findings, it has been shown that inhibition of
macroautophagy has much smaller eﬀects (if any eﬀect at
all) on the clearance of wild-type α-synuclein than on the
clearance of the mutant aggregate-prone species [27]. This is
also the case for other aggregates such as Htt in HD [28, 29].
Beclin-1 (a mammalian homologue of ATG6) is required
for the formation of the autophagosome; alterations in
beclin-1 have been linked to PD. Mutations in the PTEN-
induced putative kinase 1 (PINK1) gene also cause autosomal
recessive PD. The full-length PINK1 interacts with Beclin1,
and the overexpression of PINK1 significantly enhances
both basal and starvation-induced autophagy, which can be
reduced by beclin1 gene knockdown. On the other hand,
when a lentivirus expressing beclin-1 was delivered to the
brain of α-synuclein transgenic mouse, enhanced lysosomal
activation and reduction of accumulation of α-synuclein
were observed [30]. However, overexpression of both mutant
and wild type α-synuclein may also be accompanied by the
induction of macroautophagy [31]. Moreover, functional
deficiency of DJ-1 (associated with familiar forms of PD),
and mutant forms of LRRK2 (leucine-rich repeat kinase 2,
also linked to PD), lead to increased autophagy in murine
and human cells [32] and in transfected cells [33].
Although neuronal autophagy appears primarily to be a
protective process in the nervous system, it can also play a
paradoxical role in neuronal death. With respect to the role
of autophagy in neuronal death, several studies employing
PD toxins, a mutant familial PD gene, and postmortem PD
brains have demonstrated an important role for autophagy
in promoting the death of dopamine neurons. For example,
autophagic cell death has been observed in nigral dopamine
neurons of PD patients [34]. MPP+ or dopamine toxicity-
induced oxidative stress increases the number of AVs, auto-
phagy, and cell death, all of which diﬀers from what is
observed in starvation-induced autophagy [35]. These stud-
ies suggest that pathogenic autophagy associated with neu-
ronal death occurs and may be distinct from basal neuronal
autophagy. The contribution of autophagy and autophagic
cell death to degeneration of dopamine neurons may vary
depending on the initial cause and specific cellular context
[36]. A better understanding of autophagic stress and further
identification of autophagic cell death mechanisms may lead
to therapeutics that help restore homeostasis to dopamine
neurons in PD.
4. Chaperone-Mediated Autophagy
Several of the 10 genes known to be mutated in association
with PD encode proteins with sequences compatible with
the CMA-targeting motif [16]. α-synuclein is degraded by
macroautophagy (as discussed earlier) but also by CMA
[27, 37]. Interestingly, it has been reported that mutant α-
synuclein cannot be degraded by CMA, but, in addition, it
seems to act as a blocker for other proteins using this path-
way. Moreover, in sporadic Parkinson, where no mutations
of α-synuclein are found, dopamine adducts of α-synuclein
[38] behaved like the mutant protein, that is inhibiting cel-
lular CMA process [39]. Other proteins like the myocyte-
specific enhancer transcription factor 2D (MEF2D), that is, a
bona fideCMA substrate [40], have been observed to increase
their cytosolic levels in mice models of PD, in PD patients
[41] and in neurons with partial blockage of CMA [40]. In
these reports, blockage of CMA process seems to be a causal
factor in the onset of PD.
5. Mitocondria ROS/RNS and Autophagy
Mitochondrion is the major source of ATP in the cell; this
energy is obtained via a multistep process where carbons
atoms are oxidized to CO2. Damaged mitochondria are
accumulated, and that contributes to ineﬃcient oxygen
reduction. As a result, highly reactive species both oxygen
and nitrogen derived (ROS/RNS) are formed. Defective
mitochondria are not the only source of ROS and RNS, but,
regardless of their source, reactive species can in turn target
mitochondria (Figure 2). Cells have eﬃcient systems to
detoxify ROS and RNS. When there is an excess of reactive
species due to altered balance in the production and removal
of ROS/RNS, pathological conditions such as PD and other
neurodegenerative diseases associated occur [42–44]. It is
generally accepted that autophagy is responsible for dimin-
ishing ROS/RNS damage, but, given the variety of reactive
molecules and their location, it is yet not clear whether this
is the case in every situation. Specific forms of ROS and RNS
include hydrogen peroxide (H2O2), superoxide (O2
•−), nitric
oxide (NO), and peroxynitrite (ONOO−). Lipid peroxida-
tion is a consistent feature of neurodegenerative diseases, and
biologically active RLS, such as HNE (4-hydroxynonenal),
accumulates in brains of patients with PD and AD [45–47].
The aggressiveness of these molecules makes them toxic
to the cells; they react with proteins and lipids, inactivating
them or making them prone to aggregation. For instance, α-
synuclein and parkin have been found to be S-nitrosylated
(addition of NO to thiol groups) in relation to PD [48].
Nitrogen modified α-synuclein makes the protein prone to
aggregation [49, 50], and S-nitrosylation of parkin inacti-
vates it [51]. It was recently shown that parkin is selectively
recruited to damage mitochondria by PINK1, a mitochon-
drial serine/threonine kinase, and another recessive autoso-
mal mutated gene linked to inherited forms of PD. PINK1
is usually present at low levels on the mitochondrial mem-
brane [52]. When the mitochondrial membrane potential
is dissipated, full-length PINK1 is accumulated in the outer
mitochondrial membrane. Thus, damage to mitochondria
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Figure 2: ROS/RNS production as a result of defective mitochondria respiratory activity can be induced by a number of factors like protein
aggregates. Reactive species can also be generated by other cellular oxidases. These ROS/RNS species can modify several proteins which can
stimulate and/or inhibit autophagy. In addition, reactive species produced or not in the mitochondria can target this organelle and induce
further damage to it.
facilitates the rapid accumulation of PINK1, and, subsequent
to it, parkin is recruited to the mitochondria to induce
mitophagy [53]. This discovery revealed a link between the
mitochondrial quality control and proteins mutated in fami-
lial PD. Moreover, it further implicates a failure to eliminate
dysfunctional mitochondria in the pathogenesis of PD. In
addition, the voltage-dependent anion channel 1 (VDAC1)
is a target for parkin-mediated polyubiquitination of Lys 27
and mitophagy [54]. Thus, pathogenic parkin mutations,
together with PINK1 mutations, could lead to the disruption
of mitochondrial recruitment of parkin, ubiquitination of
mitochondrial substrates, formation of AVs, and the final
clearance of damaged mitochondria via mitophagy. This
putative role of PINK1 as a “guardian of mitochondrial
integrity” seems to be confirmed by reports of PINK1 and
parkin knockout models, where an accumulation of dam-
aged mitochondria in various tissues including dopamine
neurons occurs [55, 56]. Moreover, α-synuclein also targets
to mitochondria, where it causes a decrease in complex I
activity and/or mitochondrial damage [57, 58]. This mito-
chondrial damage causes an increase in mitophagy, presum-
ably as an attempt to clear damaged mitochondria [59]. If
mitophagy was not adequate for clearance of dysfunctional
mitochondria, these deficiencies could contribute to cell
death and neurodegeneration [60–62]. Altogether, these
observations suggest that neuronal autophagy is essential for
the turnover of damagedmitochondria and that the failure to
induce mitophagy may underlie the selective dopaminergic
neuronal loss observed in PD. This notion led to postulate
that stimulation of mitophagy in dopaminergic neurons
could serve as a therapeutic target to slow disease progression
in PD. However, other reports show that PINK1 loss of func-
tion mutation, can also induce the opposite eﬀect, induction
of mitophagy [63]. On the other hand, mutations in LRRK2,
an autosomal dominant gene involved in PD, have been
shown to induce or inhibit autophagy depending on the cell
type [33, 64].
6. Concluding Remarks
We have reviewed some of the mechanisms underlying gene
mutations associated with autophagy in PD familial cases.
Autophagy is a natural cell process to remove protein aggre-
gates, dysfunctional mitochondria, and other potentially
toxic proteins or organelles. Whether protein aggregates
observed in neurodegenerative disorders are causal factors in
the onset of disease is still an open debate. Consistent with
this controversy, both deficits and stimulation of autophagy
have been reported to underlie neurodegeneration. Thus,
current scientific evidence shows that altered protein and
organelle clearance, either by excess or deficit, are involved
in the onset of PD. However, the mechanisms that could
explain this apparently paradoxical behavior are not clear,
and further investigation is required in order to use the auto-
phagy machinery and mitochondria and protein-aggregates
removal as an eﬀective and safe therapeutic strategy in the
treatment of familial and sporadic PD.
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